Please use this identifier to cite or link to this item: https://doi.org/10.1186/1750-1172-6-79
Title: Benefits, challenges and obstacles of adaptive clinical trial designs
Authors: Chow, S.-C 
Corey, R
Keywords: clinical trial (topic)
computer program
computer simulation
dose calculation
drug research
food and drug administration
methodology
phase 1 clinical trial (topic)
phase 2 clinical trial (topic)
phase 3 clinical trial (topic)
review
statistical analysis
United States
article
bioassay
dose response
drug industry
human
methodology
sample size
standard
treatment outcome
Clinical Trials as Topic
Data Interpretation, Statistical
Dose-Response Relationship, Drug
Drug Industry
Endpoint Determination
Humans
Research Design
Sample Size
Treatment Outcome
United States
United States Food and Drug Administration
Issue Date: 2011
Publisher: BMC
Citation: Chow, S.-C, Corey, R (2011). Benefits, challenges and obstacles of adaptive clinical trial designs. Orphanet Journal of Rare Diseases 6 (1) : 79. ScholarBank@NUS Repository. https://doi.org/10.1186/1750-1172-6-79
Rights: Attribution 4.0 International
Abstract: In recent years, the use of adaptive design methods in pharmaceutical/ clinical research and development has become popular due to its flexibility and efficiency for identifying potential signals of clinical benefit of the test treatment under investigation. The flexibility and efficiency, however, increase the risk of operational biases with resulting decrease in the accuracy and reliability for assessing the treatment effect of the test treatment under investigation. In its recent draft guidance, the United States Food and Drug Administration (FDA) expresses regulatory concern of controlling the overall type I error rate at a pre-specified level of significance for a clinical trial utilizing adaptive design. The FDA classifies adaptive designs into categories of well-understood and less well-understood designs. For those less well-understood adaptive designs such as adaptive dose finding designs and two-stage phase I/II (or phase II/III) seamless adaptive designs, statistical methods are not well established and hence should be used with caution. In practice, misuse of adaptive design methods in clinical trials is a concern to both clinical scientists and regulatory agencies. It is suggested that the escalating momentum for the use of adaptive design methods in clinical trials be slowed in order to allow time for development of appropriate statistical methodologies. © 2011 Chow and Corey; licensee BioMed Central Ltd.
Source Title: Orphanet Journal of Rare Diseases
URI: https://scholarbank.nus.edu.sg/handle/10635/178164
ISSN: 1750-1172
DOI: 10.1186/1750-1172-6-79
Rights: Attribution 4.0 International
Appears in Collections:Staff Publications
Elements

Show full item record
Files in This Item:
File Description SizeFormatAccess SettingsVersion 
10_1186_1750-1172-6-79.pdf393.46 kBAdobe PDF

OPEN

NoneView/Download

SCOPUSTM   
Citations

36
checked on Feb 19, 2021

Page view(s)

20
checked on Feb 18, 2021

Google ScholarTM

Check

Altmetric


This item is licensed under a Creative Commons License Creative Commons